Bright Uro, a company specializing in care for lower urinary tract dysfunction (LUTD) through innovations in urodynamics, today announced the launch of the Glean Registry — enabling the collection of de-identified information to capture key findings and insights from commercial use of the Glean Urodynamics System. The registry marks a significant milestone as Bright Uro continues its efforts to build the future of urodynamics.
The Glean Registry will help build a comprehensive data repository, enabling the company to generate meaningful insights for clinicians treating patients across the entire range of LUTD, including overactive bladder (OAB), stress urinary incontinence (SUI), benign prostatic hyperplasia (BPH), and neurogenic LUTD (NLUTD). Enrollment into the Registry is actively underway for current Glean users.
"This Registry reflects our commitment to building the most advanced diagnostic devices and data science for the field of urodynamics. The data we collect will enable us to teach algorithms what previously took years of education and experience. Ultimately, our goal is to use technology to usher in a new era for the field of urodynamics and this Registry will help ensure we deliver on our mission of providing a superior urodynamics experience for clinicians," said Dr. Scott MacDiarmid, CMO, Bright Uro.
Urodynamics evaluates how well the bladder, sphincters, and urethra store and release urine, and is central to diagnosing conditions affecting an estimated 80 million Americans. The Registry aggregates de-identified patient data and clinician findings into a high-quality dataset to inform future device development and clinical research — and to power the development of Urodynamic Intelligence, Bright Uro's proprietary AI and ML platform that produces trained algorithms that enhance the interpretation of urodynamic test results.
"Building Urodynamic Intelligence is only possible because Glean delivers clean, consistent signals from proprietary sensing mechanisms and a connected device ecosystem. This will allow us to quickly amass the largest repository of high-quality urodynamics data and develop the most impactful AI and ML algorithms in the field. Urodynamic Intelligence will help clinicians maximize the value of every test and reveal so much more about true, physiologic bladder function. To say this will change the game is an understatement," said Derek Herrera, Founder and CEO, Bright Uro.
The launch of the Glean Registry reflects Bright Uro's continued commitment to building the evidentiary foundation that market leadership demands. By establishing a durable, scalable data asset leveraging the only wireless, catheter-free urodynamics platform on the market, Bright Uro is positioning Glean to rapidly become the standard of care for urodynamic evaluation.
